Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin

ABSTRACT

An unexpectedly high rate of adverse events and deaths were reported from November 2007 to April 2008 in patients exposed to heparin. Investigations on the quality of heparin revealed an oversulfated chondroitin sulfate (OSCS) contaminant in the heparin. Several reports on the chemical structure and limited biologic actions of OSCS have recently become available. However, no data are available on its anticoagulant and antiprotease effects. Moreover, its interaction with heparin, resulting in the modulation of heparin's anticoagulant activity, is not reported. The isolated contaminant from recalled batches of heparin and several semisynthetic OSCSs were profiled for their in vitro anticoagulant effects. The contaminant and OSCSs both exhibited measurable anticoagulant activity and produced supra-additive effects in the presence of heparin. In addition, in animal models of thrombosis and bleeding, the contaminated heparin produced stronger anticoagulant and bleeding effects than heparin. Thus, in addition to the reported biological actions, the heparin contaminant exerts measurable anticoagulant effects and interacts with heparin to produce supra-additive effects. These studies suggest that the contamination of heparin with OSCS was based on a rational design and prior knowledge of molecular and anticoagulant profiles. These studies also indicate that the OSCS contaminant may itself be heterogeneous and its molecular and biological profiles may vary in different recalled heparins.

KEYWORDS

Oversulfated chondroitin sulfate - contaminant - recalled heparins

REFERENCES

• 1 Centers for Disease Control and Prevention (CDC) . Acute allergic-type reactions among patients undergoing hemodialysis—multiple states, 2007–2008.  MMWR Morb Mortal Wkly Rep. 2008;  57 124-125
• 2 Information on adverse even reports and heparin. Rockville, MD; Food and Drug Administration 2008 Available at: http://www.fda.gov/cder/drug/infopage/heparin/adverse_events.htm
• 3 Information on heparin sodium injection. Rockville, MD; Food and Drug Administration 2008 Available at: http://www.fda.gov/drug/infopage/heparin/defualt.htm#screening
• 4 Guerrini M, Beccati D, Shriver Z et al.. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events.  Nat Biotechnol. 2008;  26(6) 669-75
• 5 Kishimoto T K, Viswanathan K, Ganguly T et al.. Contaminated heparin associated with adverse clinical events and activation of the contact system.  N Engl J Med. 2008;  358(23) 2457-2467
• 6 Ahsan A, Jeske W, Hoppensteadt D, Lormeau J C, Wolf H, Fareed J. Molecular profiling and weight determination of heparins and depolymerized heparins.  J Pharm Sci. 1995;  84(6) 724-727
• 7 Ashan A, Jeske W, Mardiguian J et al.. Feasibility study of heparin mass calibrator as a GPC calibrator for heparins and low molecular weight heparins.  J Pharm Sci. 1994;  83 197-201
• 8 Maruyama T, Toida T, Imanari T, Yu G, Linhardt R J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation.  Carbohydr Res. 1998;  306(1–2) 35-43
• 9 Dejana E, Villa S, Gaetano G et al.. Bleeding time in rats: a comparison of different experimental conditions.  Thromb Haemost. 1982;  48(1) 108-111
• 10 Raake W, Elling H. Rat jugular vein hemostasis—a new model for testing antithrombotic agents.  Thromb Res. 1989;  53(1) 73-77
• 11 Weichert W, Breddin H K. Effect of low-molecular weight heparin on laser-induced thrombus formation in rat mesenteric vessels.  Haemostasis. 1988;  18(Suppl 3) 55-63
• 12 Avorn J. Coagulation and adulteration-building on science and policy lessons from 1905.  N Engl J Med. 2008;  358 2429-2431
• 13 Schwartz L B. Heparin comes clean.  N Engl J Med. 2008;  358 2505-2509
• 14 Lormeau J C, Petitou M, Choay J. Method for obtaining biologically active mucopolysaccharides of high purity, by controlled depolymerization of heparin.  , 1987 U.S. Patent 5019649